Article

Effects of analogs of (pyro)Glu-His-Gly-OH on food consumption and gastric acid secretion in rats.

Department of Medicine, Tulane University, New Orleans, Louisiana, United States
Life Sciences (Impact Factor: 2.3). 07/1984; 34(26):2597-603. DOI: 10.1016/0024-3205(84)90046-8
Source: PubMed

ABSTRACT The effects of administration of (pyro)Glu-His-Gly-OH and its analogs on food consumption and 2-Deoxy-D-Glucose (2-DG)-induced gastric acid secretion were examined in rats. (Pyro)Glu-His-Gly-OH and (pyro)Glu-His-EA significantly reduced food consumption, but not gastric acid secretion as compared with controls. The tripeptides: (pyro)Glu-3Me-His-Gly-OH, (pyro)Glu-His-D-Ala-OH, and (pyro)Glu-Phe-Gly-OH were found to significantly inhibit 2-DG-induced gastric acid secretion. Our results indicate that some analogs of (pyro)Glu-His-Gly-OH cause a greater inhibition of food consumption or gastric acid secretion in rats than the original tripeptide, in analogy to findings obtained in dogs.

0 Followers
 · 
29 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: The effects of several superactive analogs of somatostatin on gastric acid response to various exogenous and endogenous stimulants were investigated in conscious dogs and rats with gastric fistulae (GF). The inhibition was compared to that induced by somatostatin-14 (S-S-14) at two dose levels. Several octapeptide analogs of somatostatin including D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Trp-NH2 (RC-160) and D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2 (RC-121), which were superactive in tests on suppression of GH levels, were 4-5 times more potent than S-S-14 in inhibiting desglugastrin-stimulated gastric acid secretion in GF dogs. The analog RC-160 also reduced the rise in serum gastrin levels and gastric acid secretion induced by sham feeding (SF) in dogs with gastric and esophageal fistulae (EF), but did not decrease food consumption. Gastric acid secretion induced by histamine (80 micrograms/kg/h) in dogs was not affected by 1-5 micrograms/kg/h of analog RC-121 or by 5 micrograms/kg/h of S-S-14. Analogs RC-160, RC-121, and RC-98-I (D-Trp-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2) and others also powerfully inhibited desglugastrin-induced potent as S-S-14 in dogs but its activity was higher in rats. The results indicate that octapeptide analogs which are superactive in GH-inhibition tests are also more potent than S-S-14 in suppressing gastric acid secretion. These findings may be of clinical value.
    International journal of peptide and protein research 10/1990; 36(3):267-74. DOI:10.1111/j.1399-3011.1990.tb00977.x
  • [Show abstract] [Hide abstract]
    ABSTRACT: Virtually all peptides are biologically active following central administration as a consequence of both direct and indirect cellular actions. Direct effects are mainly interactions with specific membrane receptors but may include unions with other components of the receptor/effector complex. Significant indirect biological effects of exogenous peptides, including apparent secretagogue effects on endogenous peptides largely overlooked in practice, result from extensive competition with endogenous peptides for degradative enzymes (peptidases). A consequence of this competition is enhancement of tonic or intermittent activity of endogenous peptides. The pharmacological profile of any peptide reflects or includes, therefore, the spectrum of endogenous peptides that is protected from peptidase action. It is likely that certain pharmacologically active peptides, including a large number of di-, tri- and oligo-peptides, elicit responses mainly or exclusively by competing for peptidases. Therefore, reliable estimates of the relative contributions of direct and indirect actions of exogenous peptides may be difficult, if not impossible, to obtain.
    Peptides 07/1985; 6(4-6):645-660. DOI:10.1016/0196-9781(85)90168-8 · 2.61 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: A detailed comprehension of central mechanisms underlying feeding behavior holds considerable promise for the treatment of alimentary disorders. Methods: In order to elucidate the tight interrelationships occurring at the hypothalamic neuronal endings between aminergic neurotransmitters and co-localized appetite modulators, we initially studied the effects of two anorexigenic peptides structurally related to thyrotropin-releasing hormone (TRH, 1), namely cyclo(His-Pro) (CHP, 2) and pGlu-His-Gly-OH (3), on [(3)H]-norepinephrine and [(3)H]-dopamine release from perfused rat hypothalamic synaptosomes. Furthermore, a number of TRH and CHP analogues were synthesized and tested for their ability to influence neurotransmitter release in the selected neuronal model. Results: Peptide 3 showed only a slight inhibitory activity on norepinephrine release, whereas no effect was observed for compound 2. TRH analogue 8, metabolically stabilized by the replacement of pyroglutamate with the pyrohomocysteic acid (pHcs), was found to be inactive. Conversely, a significant inhibitory effect on dopamine and norepinephrine release was observed for the CHP-related diketopiperazines cyclo(Leu-Pro) (11) and cyclo(His-Gly) (14). Conclusions: These results suggest a potential role for cyclo-dipeptides 11 and 14 in the hypothalamic modulation of appetite suppressant circuitry.
    Pharmacological reports: PR 07/2013; 65(4):823-35. DOI:10.1016/S1734-1140(13)71063-6 · 2.17 Impact Factor